Back to Back Heart Drug Failures at Novartis and Novo Nordisk Undercut Two Leading Theories of Cardiovascular Risk
Novartis' pelacarsen and Novo Nordisk's ziltivekimab failed in Phase 3 trials, testing different cardiovascular risk theories. Both drugs did not reduce cardiovascular events despite lowering targets. Novartis reported pelacarsen's Lp(a)HORIZON trial results, while Novo Nordisk halted ziltivekimab's HERMES and ATHENA trials. Analysts estimated pelacarsen's peak sales at $4B-$6B. Both companies have other trials ongoing.
How this was made
The 30-second read
Why it matters
Both companies face short‑term stock pressure, but the broader market may reassess the viability of Lp(a) and inflammation pathways.
Market read
First disclosure of two high‑profile cardiovascular trial failures, likely to affect biotech sector sentiment.
What to watch
The trials' negative results may be due to trial design or patient selection rather than drug efficacy.
Background
The article details recent Phase 3 failures for two major cardiovascular drug programs, explaining the scientific rationale and potential market impact.
Ticker impact
Novartis reported that its Phase 3 pelacarsen trial failed to reduce cardiovascular events in the Lp(a)HORIZON study.
potential short‑term downside as investors reassess pipeline valuation
First disclosure of a major late‑stage failure; market typically reacts negatively to such news.
Novo Nordisk halted its late‑stage ziltivekimab trials after the ZEUS study showed no cardiovascular benefit.
possible modest decline pending market reaction
First report of a high‑profile trial stop; investors may trim exposure to the drug's prospects.
Market effects
May dampen enthusiasm for Lp(a)‑lowering and IL‑6 inflammation strategies across biotech.
European pharma stocks could see broader pressure as two leading companies report setbacks.
Highlights challenges in cardiovascular outcome trials, potentially affecting global biotech valuations.
Counterpoint
Some investors may view the failures as a buying opportunity if they believe the underlying science still holds long‑term value.
Key entities
- CompanyNovartis
Swiss pharma giant reporting pelacarsen trial failure.
- CompanyNovo Nordisk
Danish pharma firm halting ziltivekimab trials.
